Medical Staff Pulse Newsletter

CS-Link Physician Update

Find out need-to-know information for Cedars-Sinai's upcoming CS-Link™ implementation.

CS-Link Physician Update - Oct. 25 (PDF)

Meetings and Events

Grand Rounds

Click here to view upcoming Grand Rounds.

Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - October 2011 (PDF)

Update Your Email Address

Please contact the Medical Staff Office at credentialing@cshs.org and let us know your preferred email address.

This is particularly important if you prefer to use a third party email account (Yahoo, Gmail, AOL, etc.). This message will also be distributed by regular mail.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Cedars-Sinai Collaborates with Leading Research Institute on Drug Development

New Collaboration on Clinical Trials, Personalized Therapies Could Lead to more Effective Cancer Treatment

Cedars-Sinai has combined efforts with the Translational Genomics Research Institute (TGen) in Arizona so researchers may offer joint clinical trials and collaborate to develop personalized therapies that could lead to more effective cancer treatments.

Physician-scientists at the two institutions, as part of this collaboration, will team up for Phase 1 clinical trials of new anticancer therapies aimed at molecular targets in prostate, kidney, bladder and colorectal cancers. Research also will be conducted on drugs for the less common adrenal, neuroendocrine and thyroid cancers.

"Our two organizations share the same goal: to greatly improve cancer treatment with therapies that attack the disease in new and innovative ways," said Steven Piantadosi, MD, PhD, Phase One Foundation chair and director of the Samuel Oschin Comprehensive Cancer Institute. "Translating new research into effective therapies will improve the lives of cancer patients, and, ultimately, lead to a time when cancer is a manageable condition, not a feared disease."

The collaborative endeavor also will study new approaches to improve patients' quality of life during cancer treatment and create innovative models to deliver supportive care and services to cancer survivors.

Cedars-Sinai has one of the largest clinical research trial facilities of any private hospital in the nation. Its outpatient cancer center treats more than 9,000 patients each year, making it one of the busiest treatment facilities in California. Earlier this year, the institute's cancer program was named as one of the top in the country by U.S. News & World Report's 2010-11 "Best Hospitals" issue.

The drug development research collaboration will be coordinated by Cedars-Sinai with Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.